#EURECART - Twitter Hashtag

about 5 years ago

What are the regulatory issues and challenges in Europe to harmonise translation of CAR-T therapies from bench to bedside? EATRIS Partners in @EURECART_EU report their findings in a new white paper. 👉 Find out more here: https://t.co/fPgEg4Ofnk #EURECART #CARTcell #ATMP

EatrisEric's tweet photo. What are the regulatory issues and challenges in Europe to harmonise translation of CAR-T therapies from bench to bedside? EATRIS Partners in @EURECART_EU report their findings in a new white paper.

👉 Find out more here: https://t.co/fPgEg4Ofnk #EURECART #CARTcell #ATMP https://t.co/SQShW1J0eW

0

2

0

EURE-CART Project @EURECART_EU

about 5 years ago

The regulatory barriers were a challenge for the progress of the #EURECART project. Dr. Galli of @istsupsan explains what needs to be done to foster future developments in the harmonisation process for the benefit of upcoming #clinicaltrials with #CARTcell medicinal products.

EURECART_EU's tweet photo. The regulatory barriers were a challenge for the progress of the #EURECART project. Dr. Galli of @istsupsan explains what needs to be done to foster future developments in the harmonisation process for the benefit of upcoming #clinicaltrials with #CARTcell medicinal products. https://t.co/tKKoZlZrc4

0

2

1

0

EURE-CART Project @EURECART_EU

about 5 years ago

#AdoptiveImmunotherapy with #CARTcells is an innovative therapeutic concept gainst #cancer, as #acutemyeloidleukaemia and #multiplemyeloma. The #EURECART consortium wants to bring the EU at its forefront. 🇪🇺 🧬🧑‍🔬🧪 Project partner @H_Einsele explains why this mission is crucial.

EURECART_EU's tweet photo. #AdoptiveImmunotherapy with #CARTcells is an innovative therapeutic concept gainst #cancer, as #acutemyeloidleukaemia and #multiplemyeloma. The #EURECART consortium wants to bring the EU at its forefront. 🇪🇺 🧬🧑‍🔬🧪 Project partner @H_Einsele explains why this mission is crucial. https://t.co/h99uewFxWN

0

3

0

EURE-CART Project @EURECART_EU

about 5 years ago

#CARTcells are genetically modified cells under the category "Genetically Modified Organisms and Micro-organisms" (#GMO/#GMMO) for which apply special regulatory issues for #clinicaltrials. Dr. Capone of @istsupsan outlines her main lessons learnt from the #EURECART project.

EURECART_EU's tweet photo. #CARTcells are genetically modified cells under the category "Genetically Modified Organisms and Micro-organisms" (#GMO/#GMMO) for which apply special regulatory issues for #clinicaltrials. Dr. Capone of @istsupsan outlines her main lessons learnt from the #EURECART project. https://t.co/EWOLX5aet5

0

2

3

0

EURE-CART Project @EURECART_EU

about 5 years ago

Due to regulatory barriers (obtain #clinicaltrial approval in all EU member states), #EURECART could not conduct the #multicentertrial as originally planned. Project partners make suggestions for harmonizing clinical trials with #CARTcell medicinal products in the European Union.

EURECART_EU's tweet photo. Due to regulatory barriers (obtain #clinicaltrial approval in all EU member states), #EURECART could not conduct the #multicentertrial as originally planned. Project partners make suggestions for harmonizing clinical trials with #CARTcell medicinal products in the European Union. https://t.co/ewlJ89CNlg

0

4

3

0

EURE-CART Project @EURECART_EU

about 5 years ago

📢 #PressRelease out! -> After 4,5 years of #reserach, #EURECART shares its experience on #CARTcellTherapy development with respect to regulatory issues and challenges in the harmonisation process from bench to bedside. #AML #multiplemyeloma 🧬🔬📰👉https://t.co/qyMbd4UHlj

EURECART_EU's tweet photo. 📢 #PressRelease out! -> After 4,5 years of #reserach, #EURECART shares its experience on #CARTcellTherapy development with respect to regulatory issues and challenges in the harmonisation process from bench to bedside. #AML #multiplemyeloma
🧬🔬📰👉https://t.co/qyMbd4UHlj https://t.co/PfjEiqw6jB

0

7

3

0

EURE-CART Project @EURECART_EU

about 5 years ago

Ultimate goal of #EURECART was to demonstrate the safety & efficacy of #CARTcell #immunotherapy in a multicentre first-in-man Phase I/IIa #clinicaltrial. The EU's regulatory framework for #CARTcell clinical trials challenged this mission. Stay tuned to find out more! 👩‍🔬🧪🧑‍🔬🔬🧬